Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Cancer Financing M & A

Invitae Acquires Genosity In $200M Deal, Raises $1.15Bn From Softbank Group

  • News

Executive Summary

Invitae continues its growth initiative with a $1.15bn investment from Softbank Group and acquisition of Genosity to accelerate oncology testing.

You may also be interested in...



Newer Therapy Areas Will Drive Women’s Health Funding In 2024

Women’s health startups focusing on areas of high unmet need such as menopause, infertility, preventive care and post-partum care will continue to attract investors in 2024. Meanwhile, machine learning and AI, as well as next-generation treatments such as psychedelic therapy, stand to drive advancements in the space.

News We’re Watching: Boston Scientific Closes Relievant, Medtronic's PFA Earns CE Mark, And More

Medtech Insight's News We're Watching highlights medtech industry news developments you may have missed over the last few weeks.

Smith & Nephew To Acquire CartiHeal For Up To $330M

Smith & Nephew said it will acquire sports medicine technology company CartiHeal for up to $330m to boost its knee injury repair portfolio.

Table

View full table

Topics

Related Companies

Tags:
Cancer Financing M & A
Latest Headlines

Medtech Industry Weighs In On EMA’s AI Regulation Proposals

Medtech Advocate Announces Retirement From House Of Representatives

More Nightmares For Philips DreamStation Machines

Latest Notified Body Designated Under the EU’s MDR Is A Software Specialist

See All
UsernamePublicRestriction

Register

MT143746

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By